A Multicentre, Randomised, Double-Blind, Placebo-Controlled, 5-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of 4 Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Short title: Rotigotine for the Treatment of Restless Legs Syndrome in Adults

Background

Restless legs syndrome is a disorder of the nervous system. The main symptoms include an unpleasant feeling in the legs and an uncontrollable urge to move the legs. Most of the patients are facing difficulty in falling asleep and staying asleep.

Purpose of the study

To determine if treatment with rotigotine (Neupro®) transdermal patch for 24 hours can be helpful in patients with idiopathic (i.e., of unknown cause) restless legs syndrome, both during the day and at night.

To determine if rotigotine is well tolerated by these patients.

Study participants

The study included 505 adult female and male patients aged 18 to 75 years with idiopathic restless legs syndrome.

These patients either had not received treatment for restless legs syndrome previously or had shown improvement of symptoms with dopaminergic medicines.

Study design and research methodology

The study was conducted in 60 centres in the United States between May 2005 and November 2006. Patients participated in the study for a maximum of 8 months.

The study participants were randomly equally divided into 5 groups and were given either different doses of rotigotine or a placebo via a transdermal patch every 24 hours.

After 6 months, the patients were followed to see whether symptoms of restless legs syndrome had improved and how they felt overall.

Side effects were also studied.

Key findings

More patients treated with rotigotine transdermal patches showed improvement in symptoms compared with placebo.

- Patients in the rotigotine groups (particularly higher doses) had less severe symptoms of restless legs syndrome and generally felt better compared with patients in the placebo group both during the day and at night.

- Similar number of patients who were given rotigotine or who were given placebo experienced side effects.

- The most common side effects reported in at least 5% of patients in either group were skin reactions at the site of patch application, nausea, somnolence (drowsiness), headache, insomnia (difficulty falling asleep or staying asleep), dry mouth, pruritus (itching), fatigue and dizziness.

- Most of the side effects were mild to moderate.

- Patients who completed this study were followed for an additional period of up to 1 year to further assess the long-term safety of rotigotine [NCT00263068].

Peer-reviewed publication


References:

2. An open-label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic Restless Legs Syndrome (RLS) [NCT00263068].
   http://www.clinicaltrials.gov/ct2/show/NCT00263068?term=NCT00263068&rank=1

This summary is provided for informational purposes only.
If you need medical advice about your own health or situation, please contact your physician.